| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6103248 | ARBOR PHARMS LLC | Topical preparation and therapy for head lice |
May, 2018
(5 years ago) | |
| US8927595 | ARBOR PHARMS LLC | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice |
Oct, 2027
(3 years from now) | |
| US8791153 | ARBOR PHARMS LLC | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice |
Oct, 2027
(3 years from now) | |
Sklice is owned by Arbor Pharms Llc.
Sklice contains Ivermectin.
Sklice has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Sklice are:
- US6103248
Sklice was authorised for market use on 07 February, 2012.
Sklice is available in lotion;topical dosage forms.
Sklice can be used as for head lice infestations.
The generics of Sklice are possible to be released after 12 October, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 07, 2015 |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 07 February, 2012
Treatment: For head lice infestations
Dosage: LOTION;TOPICAL
How can I launch a generic of SKLICE before it's drug patent expiration?
More Information on Dosage
SKLICE family patents
